Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / American Depositary Shares, each representing one ordinary share
-
Shares outstanding
-
40,291,821
-
Number of holders
-
15
-
Total 13F shares, excl. options
-
9,718,135
-
Shares change
-
+11,477
-
Total reported value, excl. options
-
$36,531,700
-
Value change
-
+$41,711
-
Number of buys
-
3
-
Number of sells
-
-4
-
Price
-
$3.69
Significant Holders of Barinthus Biotherapeutics plc. - American Depositary Shares, each representing one ordinary share (BRNS) as of Q4 2023
17 filings reported holding BRNS - Barinthus Biotherapeutics plc. - American Depositary Shares, each representing one ordinary share as of Q4 2023.
Barinthus Biotherapeutics plc. - American Depositary Shares, each representing one ordinary share (BRNS) has 15 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 9,718,135 shares
of 40,291,821 outstanding shares and own 24% of the company stock.
Largest 10 shareholders include M&G INVESTMENT MANAGEMENT LTD (5,197,349 shares), Alphabet Inc. (1,513,644 shares), HSG Holding Ltd (1,420,473 shares), DC Funds, LP (642,204 shares), BlueCrest Capital Management Ltd (542,673 shares), Baird Financial Group, Inc. (196,296 shares), Johns Hopkins University (107,968 shares), RENAISSANCE TECHNOLOGIES LLC (29,699 shares), Ipswich Investment Management Co., Inc. (23,075 shares), and MORGAN STANLEY (16,467 shares).
This table shows the top 15 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.